Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03705559 · ClinicalTrials.gov registry record · Phase 1
Opioid and Cannabinoid Interactions
A Phase 1 study, sponsored by Shanna Babalonis, PhD.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03705559 is a Phase 1 study that has completed, run by Shanna Babalonis, PhD. The registered enrollment target is 10 participants.
The verdict
NCT03705559, a Phase 1 study, has completed, sponsored by Shanna Babalonis, PhD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will examine the effects of doses of marijuana/placebo and doses of opioid/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction effects of these compounds.
Interventions
- DRUG Placebo
- DRUG Opioid Agonist
- DRUG Vaporized Marijuana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-06-21 |
| Est. Completion | 2024-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03705559
The ClinicalTrials.gov registry entry for NCT03705559 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shanna Babalonis, PhD, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03705559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03705559 about?
NCT03705559 is a clinical study titled "Opioid and Cannabinoid Interactions". This study will examine the effects of doses of marijuana/placebo and doses of opioid/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interacti...
What is the current status of trial NCT03705559?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-06-21. Estimated completion is 2024-02-15.
What interventions are being tested in trial NCT03705559?
The interventions under investigation include: Placebo (DRUG), Opioid Agonist (DRUG), Vaporized Marijuana (DRUG).
Who is sponsoring clinical trial NCT03705559?
This trial is sponsored by Shanna Babalonis, PhD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.